Calcium antagonists in comparison: View of the pharmacologist

Journal of Cardiovascular Pharmacology

Volumn 24, Issue 2, 1994, Pages S85-S91

  Borchard, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antiatherosclerotic action; Calcium antagonists; Pharmacodynamics; Pharmacokinetics; Vasoselectivity

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; FELODIPINE; ISRADIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ATHEROSCLEROSIS; ATRIOVENTRICULAR CONDUCTION; BINDING AFFINITY; BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; FLUSHING; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; LIPOPHILICITY; PLASMA HALF LIFE; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; VERTIGO;

ANIMAL; ARTERIOSCLEROSIS; BINDING SITES; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DOGS; HALF-LIFE; HUMAN; MUSCLE, SMOOTH, VASCULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TACHYCARDIA; VENTRICULAR FUNCTION, LEFT;

EID: 0027973656     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199412001-00013     Document Type: Article

References (21)

1. 2+ antagonists. J Cardiovasc Pharmacol 1988;12(suppl 6):S21-8.
2. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the nifedipine international trial on antiatherosclerotic therapy (INTACT). Lancet 1990;335: 1109-13.
3. Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess to effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-52.
4. Borchard U. Kalziumantagonisten. Perspektiven für die 90er Jahre. Berlin: De Gruyter, 1993.
5. Godfraind T, Salomone S, Dessy G, et al. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992;20(suppl 5):S34-S41.
6. Nayler WG. Amlodipin. Berlin: Springer-Verlag 1993.
7. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990;66:779-85.
8. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
9. Katzda S. Pharmacology of nimodipine, a calcium antagonist with preferential cerebrovascular activity. Neurochirurgia 1985;28:70-3.
10. Krieglstein J. Hirnleistungsstörungen. Pharmakologie und Ansätze für die Therapie. Stuttgart: Wissenschaft-Verlag-Gesellschaft, 1990.
11. 2+ channel blockers. Atherosclerosis 1991;88:109-32.
12. Pollack JP. Langzeittherapie über drei Jahre mit dem neuen Kalziumantagonisten Nilvadipin bei Patienten mit arterieller Hypertonie. Geriatr Forsch 1992;2:49-59.
13. Rauramaa R, Taskinen E, Seppänen K, et al. Effects of calcium antagonist treatment on blood pressure, liproteins and prostaglandins. Am J Med 1988;84(suppl 3B):93-6.
14. The MlDAS Research Group, Furberg CD, Byington RP. Multicenter isradipine diuretic atherosclerosis study (MIDAS). Am J Med 1989;86(suppl 4A):37-9.
15. Kiesewetter H, Jung F. Rheologische und mikrozirkulato-rische Wirkungen von Munobal®. 1993;1:27-35.
16. Hinke R. Vergleichende klinische Prüfung der Wirksamkeit und Verträglichkeit einer oralen Einmaldosis Nilvadipin gegen Salbutamol und Placebo bei Patienten mit chronisch obstruktiven Atemwegserkrankungen. Dissertation 1986; F3 Medizin, Th München.
17. Warltier DC, Zyvoloski MG, Gross GJ, Brooks HL. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: Systemic and coronary hemodynamics with and without combined beta adrenergic blockade. J Pharmacol Exp Ther 1984;230:367-75.
18. Holzgreve H. Die Kooperation des Patienten bei der Hochdrucktherapie. Münch Med Wochenschr 1980;122:268-72.
19. Ohtsuka M, Ono T, Hiroi J, Esumi K, Kikuchi H, Kumada S. Comparison of the cardiovascular effect of FR 34235, a new dihydropyridine, with other calcium antagonists. J Car-diovasc Pharmacol 1983;5:1074-82.
20. Futura T. Prolonged inhibitory effects of nilvadipine (FR 34235) following washout in isolated rabbit aorta and mesenteric artery. J Cardiovasc Pharmacol 1988;11:134-8.
21. Nomoto A, Hirosumi J, Sekinguchi C, Mutoh S, Yamaguchi I, Aoki H. Antiatherogenic activity of FR 34235 (nilvadipine), a new potent calcium antagonist. Atherosclerosis 1987;64:255-61.